Monoamine oxidase inhibitor sensitive site implicated in sensitization to quinpirole.
Clorgyline (1.0 mg/kg/day) administered via osmotic minipumps blocked the development of locomotor sensitization to the dopamine receptor agonist quinpirole (0.5 mg/kg every 3 days for 8 injections). In male rats already well sensitized to quinpirole, the continuous infusion of clorgyline (1.0 mg/kg/day for 28 days) produced a progressive decline in locomotor activity, despite a continued regimen of quinpirole injections (0.5 mg/kg every 3 days). It is suggested that the development, as well as the maintenance, of locomotor sensitization to quinpirole is modulated by the activation of an monoamine oxidase inhibitor-sensitive site. This site may be a dopamine D2 receptor-linked monoamine oxidase inhibitor-displaceable quinpirole binding site, the enzyme monoamine oxidase-A, or other clorgyline binding sites.
Culver
K E
KE
Department of Biomedical Sciences, McMaster University, Hamilton, Ont., Canada.
Szechtman
H
H
D000818:Animals; D001665:Binding Sites; D003010:Clorgyline / Q000008:administration & dosage / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects*; D019257:Quinpirole / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats
D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D019257:Quinpirole; D003010:Clorgyline